Synthesis, molecular docking and biological evaluation of new quinoline analogues as potent anti-breast cancer and antibacterial agents by Rathod, Shrimant V et al.
Indian Journal of Chemistry 
Vol. 60B, September 2021, pp. 1215-1222 
Synthesis, molecular docking and biological evaluation of new quinoline 
analogues as potent anti-breast cancer and antibacterial agents 
Shrimant V Rathod*
a
, Kailas W Shinde
a,b
, Prashant S Kharkar
c




 & Darshana A Raut
e
 
a Department of Chemistry, Bhavan’s Somani and Hazarimal College, Mumbai 400 007, India 
b Department of Chemistry, Wilson College, Mumbai 400 007, India 
c Department of Pharmaceutical Quality Assurance, SPTM, NMIMS, Mumbai 400 056, India 
d Department of Pharmaceutical Chemistry, SPTM, NMIMS, Mumbai 400 056, India 
e Department of Microbiology, Wilson College, Mumbai 400 007, India 
E-mail: shrees.rathod@gmail.com
Received 12 January 2020; accepted (revised) 18 August 2021 
A new class of quinoline analogues have been synthesized from isatin through two steps in good yields. They have been 
further evaluated for their anticancer activity against a breast cancer cell line (MDA-MB-231) and antibacterial activity 
against Gram-positive bacteria (Staphylococcus aureus 6538p and Bacillus subtilis) and Gram-negative bacteria 
(Escherichia coli and Pseudomonas aeruginosa). All synthesized compounds have been confirmed by spectral 
characterization viz. FT-IR, MS, HPLC, 1H and 13C NMR. Among them, compound 4h exhibits promising anti-breast cancer 
activity whereas compounds 4d, 4f, 4h and 4j exhibit moderate antibacterial activity against all the tested organisms. 
Molecular docking analysis demonstrates the interaction of compound 4h with the active site amino acid of Human 
Carbonic Anhydrase I, Protein Kinase A and Kinesin Spindle Protein (KSP). 
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Breast cancer is the most commonly diagnosed cancer 
and also causes the greatest number of cancer-related 
deaths among women. Worldwide, there will be about 
2.1 million newly diagnosed female breast cancer 
cases in 2018, accounting for almost 1 in 4 cancer 
cases among women. In 2018, it is estimated that 
6,27,000 women died from breast cancer - that is 




Antibacterial resistance is precarious to practical 
eradication and treatment of an escalating range of 
diseases caused by bacteria. Also, the treatment of 
bacterial infections remains a challenging therapeutic 
problem because of emerging infectious diseases and 
the increasing number of multidrug-resistant 
microbial pathogens. Despite the many antibiotics and 
chemotherapeutics available, the emergence of old 
and new antibiotic-resistant bacterial strains in the last 




Quinolines are important pharmacophores which 
have evoked considerable attention in recent years in 
view of their wide range of pharmacological 














. The quinoline moiety has increasingly 
attracted the attention of synthetic chemists. The 
anticancer and antibacterial activity of numerous 
quinoline derivatives has been studied and well 
documented in the literature
10-21
. 
Based on this trend, it was expected in the present 
work that the incorporation of substituents on the 
quinoline skeleton could produce derivatives with 
enhanced biological properties. In order to further 
expand the scope of quinoline derivatives as 
privileged medicinal scaffold, we have been engaged 
in anticancer and antibacterial evaluation of new 
quinoline analogues so as to develop novel molecules 
which could possibly find applications as potential 
anticancer and antibacterial agents. Thus, a new 
class of quinoline derivatives bearing carboxamide 
functionality were conveniently synthesized and 
screened for their anticancer activity (breast cancer 
cell line MDA-MB-231) and antibacterial activity 
(Gram-positive bacteria- Staphylococcus aureus 
6538p and Bacillus subtilis and Gram-negative 
bacteria- Escherichia coli and Pseudomonas 
aeruginosa). 




Result and Discussion 
 
Chemistry 
In the present work, a series of quinoline analogues 
4a-4j were synthesized from isatin in two steps as 
shown in Scheme I. Compound 4a and compound 4g 
were already reported as antitubercular agent and tubulin 
polymerization inhibitor respectively
22,23
. The key 
intermediate 3 was synthesized by the following method 
described in literature
24
. The first step involved the 
condensation of isatin 1 and acetophenone 2 in the 
presence of aqueous solution of ethanol and potassium 
hydroxide at 80°C to give 2-phenylquinoline-4-
carboxylic acid 3. Finally, the target compounds 4a-4j 
were obtained by coupling of acid chloride formed  
by refluxing intermediate 3 with POCl3 in DMF  
at 100°C for 4 h with respective amines using  
sodium hydride in THF solvent stirred at room 





All the compounds were evaluated against MDA-
MB-231 (breast adenocarcinoma) using MTT assay 
(colorimetric method). Cisplatin and Doxorubicin 
HCl were used as positive controls and the IC50 values 
are reported in µM. The results are shown in Table I. 
During analysis, it was observed that the IC50 
values of all tested compounds were found to be in 
the range of 37.99-11.50 µM. and variations were 
observed when the substituent’s (X) changed the 
positions. Compound 4d (4-F) demonstrated higher 
activity and the potency was decreased as the 
substituent (fluoro group) was shifted to 2 (4b) and 3 
(4c) position, while the compound 4h (2-NO2) was 
found to be the best molecule (IC50 = 11.50 µM) 
among all analogues and the activity was reduced as 
the substituent was moved to 3 (4i) and 4 (4j) 
position. The compounds having -OCH3 substituent 4 
(e-g) demonstrated almost same activity. It can be 
revealed from the above results that, the substituent 
(X) at 4 position exhibited superior activity than at 2 
and 3 position. All the molecules demonstrated 
potency less than 50 µM and were better than 
cisplatin but not comparable to doxorubicin. Further 
optimization of Compound 4h may give rise to potent 
candidates to develop a new anticancer drug.  
IC50 values of compounds against Cancer cell line 
MDA-MB-231 (breast adenocarcinoma) 
 
Antibacterial activity 
All the compounds were evaluated against Gram-
positive bacteria (Staphylococcus aureus 6538p  
and Bacillus subtilis) and Gram-negative bacteria 
(Escherichia coli and Pseudomonas aeruginosa). 
Streptomycin was used as a standard drug and zones 
of inhibition (mm) were noted. The results are shown 
in Table II. 
From antibacterial activity data, it was confirmed 
that all the compounds showed less potency compare 
to standard streptomycin. Among all the synthesized 
analogues, the compounds 4d, 4f, 4h and 4j exhibited 
moderate antibacterial activity against all the  
tested organisms. The compounds 4b, 4e, 4g and  
 
 
Scheme I — Synthesis of quinoline analogues 
 
Table I — Anticancer activity of qunoline analogues 4a-j 
Compd X IC50 ± SD (μM)
a 
4a H  37.99±1.54 
4b 2-F 35.69±2.49 
4c 3-F 24.72±1.43 
4d 4-F 16.45±0.72 
4e 2-OCH3 22.08±1.01 
4f 3- OCH3 23.03±2.25 
4g 4- OCH3 19.83±0.69 
4h 2-NO2 11.50±0.98 
4i 3-NO2 22.21±1.12 
4j 4-NO2 34.18±2.35 
Doxorubicin.HCl − 0.64±0.04 
Cisplatin − 47.95±1.26 
a Results are mean of triplicate analysis 
 




4i are active against only Gram-positive bacteria 
(Staphylococcus aureus 6538p and Bacillus subtilis). 
The compound 4a and 4c did not exhibit any 
antibacterial activity. 
 
Molecular docking studies 
In order to investigate the potential molecular 
targets of this hit molecule (4h, Table I) and to 
provide a preliminary data for the molecular/cellular 
biology, the authors carried out a target ‘go fishing’ 
experiment using PharmMapper
18
. The Pharm Mapper 
is an open-source used for screening molecules 
through a number of pharmacophore databases 
(Target Bank, Binding DB, Drug Bank and potential 
drug target database). The present study combines 
computational analyses with wet-lab to provide 
logical base for the anticancer effects of these hit 
molecule and can be useful for the exploration of the 
proposed molecular target(s) to treat cancer. 
Three targets were selected from PharmMapper 
displaying highest fitting score with the hit molecule 
4h (Table III). To identify potential interactions of the 
hit molecule, molecular docking studies were 
performed using XP mode in the GLIDE module, 
with default settings. The X-ray structure of 
hIMPDH2 was retrieved from the protein data bank 
(PDB ID: 1JR1) and optimized by using OPLS2005 
force field. The hit molecule 4h was prepared and 
optimized using LigPrepmodule as implemented in 
Schrodinger Small-Molecule Drug Discovery Suite. 
Receptor grid was generated and the docking studies 
were performed according to the standard protocol. 
Individual docked poses were inspected manually to 
observe the binding interactions of ligands with the 
selected molecular targets (Table III). 
Compound 4h showed interaction with the active 
site amino acid of Human Carbonic Anhydrase I 
(PDB ID: 1CZM), Protein Kinase A (PDB ID: 2F7X) 
and Kinesin Spindle Protein (KSP) (PDB ID: 2UYI) 
(Figure 1). Compound 4h displayed stacking 
with Hie64 and His94 in Human Carbonic  
Anhydrase I and additional interactions with Phe91 
(stacking) and hydrogen bonding interaction 
between Gln92 and amide carbonyl group were 
observed. 
In Protein Kinase A receptor, compound 4h 
Showed stacking with Phe 54 and hydrogen 
bonding interaction with Lys 72. Also in Kinesin 
Spindle Protein (KSP) receptors, the compound 4h 
showed hydrogen bonding interaction between Glu 






Materials and Methods 
All commercial chemicals and solvents are of LR-
grade and AR-grade and were used without further 
purification. The thin layer chromatography was 
performed on Merck pre-coated silica gel 60 F254 
plates, with visualization under UV light. Melting 
points were determined with (PEW-340MP) melting 
point apparatus and are uncorrected. 
1
H NMR and 
13
C 
NMR spectra were recorded with Bruker 300 MHz 
and Bruker 100 MHz ADVANCE instrument 
respectively and J values are in Hertz and chemical 
shifts (δ) are reported in ppm relative to internal 
tetramethylsilane. FTIR spectra (ν in cm-1) using  
KBr discs were recorded on Perkin-Elmer FTIR 
spectrophotometer. The mass spectra (MS) were 
measured with Thermo Finnigan-TSQ Quarter Ultra 
(triple Quad). The purity of all the compounds was 
determined by HPLC (Waters 2695 Alliance) using 
column Kromasil C18, solvent acetonitrile & buffer 
(0.01 M ammonium acetate + 0.5% triethylamine, pH 
5.0 with acetic acid).  
Table II — Antibacterial activity of qunoline analogues 4a-j 
Compd Zone of inhibition (mm) 









4a − − − − 
4b 8 6 − − 
4c − − − − 
4d 12 10 8 9 
4e 12 11 − − 
4f 13 12 10 8 
4g 10 12 − − 
4h 13 14 10 10 
4i 10 11 − − 
4j 15 16 9 10 
Strepto
mycin 
20 22 22 24 
- No Inhbition 
Results are mean of triplicate analysis 
 
Table III — Result of docking analysis of the hit compound 4h 


















General Procedure and Analytical Data 
 
Procedure for the synthesis of 2-phenylquinoline-
4-carboxylic acid, 3 
A mixture of isatin 1 (147 mg, 1 mmol) and  
250 mg potassium hydroxide in 5 ml ethanol-water 
was stirred at room temperature for 15-30 min.  
The mixture was then acidified to pH 2-3 with 0.38 
ml concentrated hydrochloric acid, and acetophenone 
2 (224 mg, 1 mmol) was added. The resulting mixture 
was stirred at 80°C for 12-13 h and a precipitate 
appeared. The reaction progress was monitored by 
TLC. After the starting material had vanished, the 
precipitate was filtered, washed with water and 
recrystallized to obtain the pure compound 3.  
White solid; Yield 77%; mp 210–212 °C; 
1
H NMR 
(DMSO-d6, 300MHz, δ ppm): 14.35 (brs, 1H), 8.87 
(d, J = 7.8 Hz, 1H), 8.22 (s, 1H), 8.15 (d, J = 9.0 Hz, 
1H), 7.85-7.89 (m, 2H), 7.78-7.81 (m, 1H), 7.65-7.69 
(m, 1H), 7.52-7.57 (m, 2H), 7.44-7.47 (m, 1H); 
13
C 
NMR (DMSO-d6, 300MHz, δ ppm): 167.52, 158.89, 
147.20, 140.38, 135.16, 133.57, 132.26, 132.16, 
131.47, 131.16, 128.52, 126.76, 125.00, 124.89, 
 
 
Figure 1 — 2D interaction diagram of molecular docking of hit 4h in the binding sites of macromolecular targets – (A1) 4h docked in the 
binding site of Human Carbonic Anhydrase I (PDB ID 1CZM). (A2) 4h docked in the binding site of Protein Kinase A (PDB ID 2F7X). 
(A3) 4h docked in the binding site of Kinesin Spindle Protein (KSP) (PDB ID 2UYI). Grey dotted lines represent hydrogen bonding 
interaction and green or red solid line indicates π−π stacking interaction. 
 




124.71, 121.57; IR (KBr) νmax/cm
–1
: 3263, 1716, 
1659, 1525, 1398, 1215, 818, 751, 692; MS (APCI): 
m/z 250.20 [M+H]
+
; HPLC: 98.93%. 
 
General procedure for the synthesis of compounds 
4a-j 
To a solution of 2-phenylquinoline-4-carboxylic 
acid 3 (2.0 mmol, 1eq.) in DMF, POCl3 (20 mmol, 10 
eq.) was added at 0°C. The reaction mixture was 
stirred at 100°C for 4 h. Completion of the reaction 
was monitored by TLC. The reaction mass was 
diluted with ice cold water, a pale yellow solid 
precipitates out was filtered and dried at suction 
pump. 
To a solution of 2-phenylquinoline-4-carboxylic 
acid chloride, (0.9 mmol, 1 eq.) in THF, respective 
amine (1.5 mmol, 1.5 eq.) and Sodium hydride  
(1.0 mmol, 1.1 eq.) was added at 0
o
C and the reaction 
mixture was then stirred at room temperature for 1 h. 
Completion of the reaction was monitored by TLC in 
ethyl acetate-petroleum ether (4:6). The reaction 
mixture was then poured into ice cold water and 
extracted with ethyl acetate. The combined organic 
phases were dried (Na2SO4) and concentrated in 
vacuum. The crude product was purified by silica gel 
(100-200 mesh) flash column chromatography (20% 
Ethyl acetate/petroleum ether) to obtain the 
compounds 4a-4j. 
 
Synthesis of N,N-2-diphenylquinoline-4-carboxamide, 
4a 
Light yellow solid; Yield 72%; mp 194-196 °C; 
1
H 
NMR (DMSO-d6, 400MHz, δ ppm): 10.82 (s, 1H), 
8.37 (t, 2H), 8.18 (d, J = 8.4 Hz, 2H), 7.82-7.88 (m, 
4H), 7.68 (t, 1H), 7.54-7.62 (m, 3H), 7.42 (t, 2H), 
7.18 (t, 1H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 
165.28, 155.81, 147.90, 143.03, 138.83, 138.12, 
130.29, 129.94, 129.61, 128.90, 128.81, 127.61, 
127.32, 125.07, 124.13, 123.25, 123.08, 121.62, 
121.54, 120.31, 119.97, 116.80; IR (KBr) νmax/cm
–1
: 
3243, 1677, 1598, 1547, 1355, 1257, 879, 756, 696; 
MS (APCI): m/z 325.40 [M+H]
+




Yellow solid; Yield 71%; mp 164-166 °C; 
1
H 
NMR (DMSO-d6, 400MHz, δ ppm): 10.69 (s, 1H), 
8.37 (d, J = 7.2 Hz, 3H), 8.18-8.24 (m, 2H), 7.85-7.94 
(m, 2H), 7.70 (t, 1H), 7.53-7.62 (m, 3H), 7.29-7.39 
(m, 3H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 
166.10, 160.92, 158.57, 149.27, 147.56, 141.40, 
137.37, 134.10, 132.69, 130.35, 129.91, 129.15, 
128.92, 128.85, 126.37, 124.05, 123.90, 123.77, 
121.34, 121.11, 119.45, 116.27; IR (KBr) νmax/cm
–1
: 
3263, 1676, 1595, 1542, 1355, 1199, 757, 695; MS 
(APCI): m/z 341.10 [M-H]
-




White solid; Yield 70%; mp 216-218 °C; 
1
H NMR 
(DMSO-d6, 300MHz, δ ppm): 10.71 (s, 1H), 8.37  
(s, 1H), 8.18-8.26 (m, 4H), 7.84-7.93 (m, 2H), 7.70  
(t, 2H), 7.58 (t, 3H), 7.33-7.37 (m, 2H); 
13
C NMR 
(DMSO-d6, 100MHz, δ ppm): 165.82, 161.76, 157.92, 
149.15, 146.71, 140.21, 138.92, 136.25, 132.25, 
131.91, 130.25, 129.91, 129.59, 127.98, 127.65, 
127.31, 125.15, 123.27, 120.25, 118.89, 116.54, 
116.22; IR (KBr) νmax/cm
–1
: 3184, 1684, 1613, 1549, 
1355, 1244, 1128, 867, 757, 699; MS (APCI): m/z 
343.20 [M+H]
+




White solid; Yield 78%; mp 222–224 °C; 
1
H NMR 
(DMSO-d6, 400MHz, δ ppm): 10.88 (s, 1H), 8.38 (d, 
J = 7.6 Hz, 3H), 8.18 (d, J = 8.4 Hz, 2H), 7.83-7.88 
(m, 3H), 7.68 (t, 1H), 7.55-7.61 (m, 3H), 7.27 (t, 2H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 165.54, 
161.21, 158.52, 148.98, 146.51, 141.21, 138.27, 
135.15, 133.25, 132.91, 131.27, 129.61, 129.39, 
127.98, 127.65, 127.31, 126.15, 125.97, 121.75, 
120.29, 116.74, 116.52; IR (KBr) νmax/cm
–1
: 3242, 
1679, 1616, 1553, 1356, 1212, 1152, 837, 755, 697; 
MS (APCI): m/z 343.20 [M+H]
+




Brown solid; Yield 78%; mp 160-162 °C; 
1
H NMR 
(DMSO-d6, 400MHz, δ ppm): 10.43 (s, 1H), 8.45 (d, 
J = 9.2 Hz, 1H), 8.29 (d, J = 7.2 Hz, 2H), 8.17 (d, J = 
8.8 Hz, 1H), 8.10 (d, J = 8.8 Hz, 2H), 8.00 (d, J = 8.4 
Hz, 1H), 7.81 (t, 1H), 7.67 (d, J = 7.2 Hz, 1H), 7.52-
7.60 (m, 3H), 7.12 (d, J = 8.4 Hz, 2H), 3.88 (s, 3H); 
13
C NMR (DMSO-d6, 75MHz, δ ppm): 165.16, 
158.81, 156.73, 149.62, 148.56, 147.34, 140.38, 
138.56, 135.16, 133.57, 132.08, 131.47, 131.16, 
129.31, 124.84, 124.34, 121.22, 118.80, 116.57, 
116.26, 112.71, 112.47, 56.62; IR (KBr) νmax/cm
–1
: 
3299, 1673, 1596, 1529, 1354, 1258, 1117, 1031, 810, 










Brown solid; Yield 75%; mp 152-154 °C; 
1
H NMR 
(DMSO-d6, 400MHz, δ ppm): 10.79 (s, 1H), 8.35 (d, 
J = 8.4 Hz, 3H), 8.15-8.18 (m, 2H), 7.83-7.87 (m, 
1H), 7.65-7.69 (m, 1H), 7.51-7.60 (m, 4H), 7.38 (d, J 
= 8.4 Hz, 1H), 7.31 (t, 1H), 6.74-6.77 (m, 1H), 3.78 
(s, 3H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 
165.31, 159.54, 155.81, 147.89, 142.98, 139.98, 
138.11, 130.31, 129.95, 129.62, 128.91, 127.38, 
127.32, 125.05, 123.14, 121.54, 118.25, 116.89, 
116.78, 112.22, 109.61, 105.75, 55.06; IR (KBr) 
νmax/cm
–1
: 3056, 1675, 1610, 1544, 1354, 1250, 







White solid; Yield 82%; mp 218-220 °C; 
1
H NMR 
(DMSO-d6, 400MHz, δ ppm): 10.67 (s, 1H), 8.37  
(d, J = 7.2 Hz, 2H), 8.32 (s, 1H), 8.17 (t, 2H), 7.85  
(t, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.67 (t, 1H),  
7.54-7.60 (m, 3H), 6.98 (d, J = 8.8 Hz, 2H), 3.77  
(s, 3H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 
165.16, 155.69, 147.82, 142.92, 138.70, 138.02, 
134.23, 131.64, 130.16, 129.80, 129.52, 128.76, 
128.68, 127.20, 124.98, 124.02, 123.08, 122.02, 
121.92, 119.75, 116.65, 116.52, 55.04; IR (KBr) 
νmax/cm
–1
: 3304, 1683, 1589, 1527, 1349, 1247, 
1179, 1030, 825, 769, 689; MS (APCI): m/z 355.20 
[M+H]
+




Yellow solid; Yield 72%; mp 180-182 °C; 
1
H 
NMR (DMSO-d6, 400MHz, δ ppm): 11.29 (s, 1H), 
8.27 (m, 3H), 8.26 (m, 2H), 8.16 (m, 1H), 7.70 (m, 
2H), 7.57 (m, 3H), 7.53 (m, 3H); 
13
C NMR (DMSO-
d6, 100MHz, δ ppm): 165.31, 158.54, 149.59, 145.15, 
140.21, 137.92, 133.27, 130.25, 129.91, 129.59, 
128.98, 128.65, 128.31, 127.92, 125.15, 123.27, 
123.15, 121.27, 121.15, 118.54, 118.22, 116.76; IR 
(KBr) νmax/cm
–1
: 3317, 1691, 1590, 1548, 1347, 
1279, 1151, 774, 749, 690; MS (APCI): m/z 370.32 
[M+H]
+




Yellow solid; Yield 74%; mp 264-266 °C; 
1
H 
NMR (DMSO-d6, 400MHz, δ ppm): 11.30 (s, 1H), 
8.88 (d, J = 1.6 Hz, 1H), 8.45 (s, 1H), 8.39 (d, J = 6.8 
Hz, 2H), 8.15-8.23 (m, 3H), 8.04-8.07 (m, 1H), 7.86-
7.90 (m, 1H), 7.68-7.75 (m, 2H),7.55-7.62 (m, 3H); 
13
C NMR (DMSO-d6, 100MHz, δ ppm): 165.38, 
159.62, 155.88, 147.97, 142.98, 140.02, 138.19, 
130.38, 129.98, 129.70, 128.98, 127.46, 127.42, 
125.12, 123.22, 121.33, 120.92, 118.78, 116.87, 
112.29, 109.70, 105.82; IR (KBr) νmax/cm
–1
: 3275, 
1691, 1631, 1543, 1526, 1354, 1109, 848, 752, 676; 
MS (APCI): m/z 370.10 [M+H]
+




Yellow solid; Yield 68%; mp 264-266 °C; 
1
H 
NMR (DMSO-d6, 400MHz, δ ppm): 11.40 (s, 1H), 
8.31 (m, 2H), 8.28 (m, 3H), 8.02 (d, J = 8.0 Hz, 3H), 
7.85 (m, 1H), 7.55 (m, 1H), 7.52 (m, 4H); 
13
C NMR 
(DMSO-d6, 75MHz, δ ppm): 165.63, 156.73, 155.77, 
153.46, 147.91, 142.40, 138.14, 130.28, 129.92, 
129.61, 128.90, 127.37, 127.31, 127.07, 126.96, 
126.23, 125.31, 125.14, 124.04, 118.48, 116.43, 
116.26; IR (KBr) νmax/cm
–1
: 3198, 1689, 1595, 1555, 
1343, 1259, 1189, 860, 758, 695; MS (APCI): m/z 
370.40 [M+H]
+







Cancer cell line MDA-MB-231 (breast 
adenocarcinoma) was purchased from National Centre 
for Cell Sciences, Pune, India. 3-(4,5-Dimethyl 
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), Tris-HCl were obtained from SRL (Mumbai, 
India), Fetal bovine serum (FBS), Phosphate buffered 
saline (PBS), Dulbecco’s modified eagle’s medium 
(DMEM) and Trypsin-EDTA were obtained from 
CellClone (Delhi, India), antibiotics from Hi-Media 
Laboratories Ltd. (Mumbai, India). 
 
Anti-cancer assay 
Briefly, cells were grown in DMEM media 
supplemented with fetal bovine serum (FBS) 10%  
(50 µg/ml) and penicillin-streptomycin (50 µg/ml) at 
37°C, CO2 (5%) and air (95%). Cells were seeded 
(1x10
4
 cells/well) in each of the 96-well plate for 
different concentration of synthesized compounds 
ranging from 0.01 to 100 μM. After incubation, 6 
concentrations (triplicate) of test compounds 
(prepared in DMSO) were added to the cells and 
incubated at 37°C and 5% CO2 for 48 h. 20 µL of 
MTT solution (5 mg/mL) was then added to each 




well. Plate was further incubated for a period of about 
4 h, the supernatant was removed and 200 µL per well 
DMSO was added to solubilize formazan crystals. 
Plate was incubated for 10 min and absorbance  
was measured at 540 nm. (IC50 determination at 





The Gram-positive organisms viz. Bacillus subtilis 
and Staphylococcus aureus 6538p and Gram-negative 
organisms viz. Pseudomonas aeruginosa and 
Escherichia coli cultures were obtained from 
neighbouring hospitals and pathological laboratories 
located in Mumbai. 
 
Antibacterial assay 
The Antibacterial activity of all quinoline 
derivatives was checked by agar well diffusion 
method. The synthesized compounds were diluted to 
obtain final concentration of 32µg/ml using HPLC 
grade DMSO. The sterile molten Mueller and Hinton 
agar butt was seeded with 0.4 mL of 24 hr old test 
pathogens (0.1 OD at 540 nm). The seeded NA butt 
was poured into sterile Petri plates. After 
solidification of medium, compounds were allowed 
to diffused into the punched wells. After incubation 
at 37°C for 24 h, the resulting zones of inhibition 
were measured in millimetres. The derivatives 
showing the maximum zone of inhibition against test 
pathogens were checked. The experiment was done 
in triplicates and the result was reported as mean 
standard deviation. Solvent and growth controls 
were kept and streptomycin was used as a standard 
drug and zones of inhibition (mm) were noted. 
 
Molecular docking 
Hardware and Software: All the molecular 
modelling studies described herein were performed on 
HP Laptop (Intel® Core™i7-5500T CPU @ 2.40 
GHz, RAM 4 GB) running Windows 8.1 64-bit 
HomeBasic Operating System. Schrodinger Small-
Molecule Drug Discovery Suite Release 2018-1 [49] 
and the products included therein were used for 




In summary, new class of quinoline analogues were 
prepared and also revealed their SAR information. 
Based on the analysis done, we can conclude that all 
the compounds showed significant anticancer  
activity against a breast cancer cell line (breast 
adenocarcinoma, MDA-MB-231) and the trends were 
observed with variations in the substituents (X). The 
substituent (X) is favoured 4 position more than 2 and 
3 position to exhibit superior potency. Compound 4h 
exhibited better promising anticancer activity among 
various synthesized molecules. Molecular modelling 
results provided additional insight into the interaction 
of compound 4h with the active site amino acid of 
Human Carbonic Anhydrase I, Protein Kinase A and 
Kinesin Spindle Protein (KSP). These current results 
will help us to further optimize and develop new drug 
candidates in future. 
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